Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Baume

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Cancer|July 1, 1988
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimenM Ghosn, J P Droz, C Theodore, et al.
European Cytokine Network|September 1, 1996
Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinomaP Viens, G Gravis, F Bladou, et al.
British Journal of Haematology|July 1, 1993
A tumour-associated antigen expression in human haematological malignanciesH Chambost, F Brasseur, P Coulie, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|April 1, 1992
Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancerP Viens, D Blaise, A M Stoppa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 1, 1989
Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-RoussyJ M Cosset, D Baume, J L Pico, et al.
Acta Endocrinologica|July 1, 1993
Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignanciesB Vialettes, M A Guillerand, P Viens, et al.
Cancer|March 26, 1999
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel studyT Dorval, S Négrier, C Chevreau, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 27, 1999
Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patientsN Vey, D Blaise, M Lafage, et al.
European Cytokine Network|February 12, 1998
Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantationN Vey, P Viens, C Fossat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignanciesT Girinsky, E Benhamou, J H Bourhis, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Cancer|July 1, 1988
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimenM Ghosn, J P Droz, C Theodore, et al.
European Cytokine Network|September 1, 1996
Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinomaP Viens, G Gravis, F Bladou, et al.
British Journal of Haematology|July 1, 1993
A tumour-associated antigen expression in human haematological malignanciesH Chambost, F Brasseur, P Coulie, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|April 1, 1992
Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancerP Viens, D Blaise, A M Stoppa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 1, 1989
Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-RoussyJ M Cosset, D Baume, J L Pico, et al.
Acta Endocrinologica|July 1, 1993
Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignanciesB Vialettes, M A Guillerand, P Viens, et al.
Cancer|March 26, 1999
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel studyT Dorval, S Négrier, C Chevreau, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 27, 1999
Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patientsN Vey, D Blaise, M Lafage, et al.
European Cytokine Network|February 12, 1998
Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantationN Vey, P Viens, C Fossat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignanciesT Girinsky, E Benhamou, J H Bourhis, et al.
Pageof 6